ANIK Stock Analysis: Buy, Sell, or Hold?
ANIK - Anika Therapeutics Inc
$19.69
-1.04 (-5.04%)
▼
5d:
+29.97%
30d:
+22.83%
90d:
+35.33%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When ANIK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ANIK is 12.1% above its trading range ($17.56). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ANIK is 12.1% above its trading range ($17.56). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.53
Based on -2.7% avg growth
INTRINSIC VALUE TODAY
$12.75
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANIK is currently trading at $19.69, which is considered extended relative to its 30-day fair value range of $14.48 to $17.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.8) compared to its historical average (35.7). Remarkably, the market is currently pricing in an annual earnings decline of 15.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANIK is in a uptrend. Immediate support is located at $14.58, while resistance sits at $21.11. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: ANIK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ANIK is in a uptrend. Immediate support is located at $14.58, while resistance sits at $21.11. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: ANIK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$14.48 -
$17.56
Company Quality Score
57/100
(HOLD)
Options IV Signal
16th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
53.8%
Protect Your Profits
ANIK is technically overbought (RSI 82). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+12.1% above its trading range)
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- NEUTRAL: Near Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$14.48 -
$17.56
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.82
(4.2%)
Support & Resistance Levels
Support Level
$14.58
Resistance Level
$21.12
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.83
Wall Street Target
$21.00
(+1.3%)
Revenue Growth (YoY)
15.6%
Earnings Growth (YoY)
-50.5%
Profit Margin
-3.1%
Valuation Discount vs History
-15.1% cheaper
PE vs Historical
21.8 vs 35.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.1%
(market-implied from PE analysis)
1-Year Target
$18.66
(-10%)
2-Year Target
$16.80
(-19%)
3-Year Target
$15.12
(-27%)
3-Yr Target (if PE normalizes)
(PE: 22→36)
$24.72
(+19%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -9.5%)
$15.36
(+-26%)
Base:
(SPY PE: 20.7, Growth: -9.5%)
$14.59
(-30%)
Bear:
(PE: 17.6, Growth: -9.5%)
$12.40
(-40%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.8 to 35.7
Stabilization Target:
$33.92
(+63.6%)
PE Expansion Potential:
+63.6%
Share & Embed Analysis
Last updated: August 04, 2026 9:59 AM ET
Data refreshes hourly during market hours. Next update: 10:59 AM
Data refreshes hourly during market hours. Next update: 10:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
Advanced ANIK Option Strategies
Professional options setups generated by AI based on today's ANIK price and gamma walls.
